Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed neuroendocrine tumor (NET) * Carcinoid at any site, with or without carcinoid syndrome * Pancreatic islet cell tumor * Prior streptozocin-based therapy not required * Poorly differentiated NET of any primary site (this arm closed to accrual May 2009) * Progression with prior treatment with cisplatin-, or carboplatin-based chemotherapy required (unless contraindicated) * The following tumors are not allowed: * Endocrine organ carcinoma * Adrenal gland malignancies * Thyroid carcinoma of any histology * Pheochromocytoma/paraganglioma * Advanced disease * Disease not amenable to surgery, radiotherapy, or combined modality therapy with curative intent * Radiologically or clinically confirmed progressive disease * At least 25% increase in radiologically or clinically measurable disease * At least 20% increase in the longest diameter (LD) of any previously documented lesion * Increase in the sum of the LD of multiple lesions in aggregate of 20%, OR appearance of new lesions OR deterioration in clinical status * Measurable disease * At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional radiographic techniques OR ≥ 10 mm by spiral CT scan * Ultrasound or positron-emission tomography alone not sufficient * Bone lesions, ascites, peritoneal carcinomatosis, pleural or pericardial effusion, and irradiated lesions are not considered measurable disease * Primary tumors of the pancreas should not invade adjacent organs (e.g., stomach or duodenum) * No history or evidence of brain or leptomeningeal disease (baseline CNS imaging required if clinical suspicion of CNS metastases) PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-1 Life expectancy * More than 12 weeks Hematopoietic * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * No history of hemoptysis or bleeding diathesis * No coagulopathy unrelated to therapeutic anticoagulation * No significant bleeding events within the past 6 months unless the source of the bleeding has been resected Hepatic * Bilirubin \< 2 mg/dL * ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if due to liver metastases) Renal * Creatinine ≤ 2 mg/dL * Protein ≤ 1+ OR * Protein \< 1 gm on 24-hour urine collection * Urine protein:creatinine ratio \< 1.0 Cardiovascular * History of thromboembolic condition allowed provided patient is on therapeutic anticoagulation at a stable dose for ≥ 4 weeks * Concurrent daily prophylactic aspirin (\< 325 mg/day) allowed * No uncontrolled hypertension, myocardial infarction, clinically significant peripheral arterial ischemia, visceral arterial ischemia or angina within the past 6 months * No serious cardiac arrhythmia requiring medication * No cerebrovascular event (e.g., stroke or transient ischemic attack) within the past 12 months * No history of peripheral vascular disease ≥ grade 2 * No history New York Heart Association class II-IV congestive heart failure * Blood pressure ≤ 160/90 mm Hg Gastrointestinal * No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months * No predisposing uncontrolled small bowel or colonic disorder * Baseline disease-related diarrhea allowed if symptoms are stable and well-characterized (i.e., # stools/day stable) * No gastric or esophageal varices * No gastroduodenal ulcers determined to be active by endoscopy Pulmonary * No interstitial pneumonia or extensive and symptomatic interstitial fibrosis * No lung tumor in close proximity to a major vessel, or with associated cavitation * No pleural effusion or ascites that causes ≥ grade 2 dyspnea Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for at least 3 months after completion of study treatment * No significant traumatic injury within the past 28 days * No currently active second malignancy other than, non-melanoma skin cancer or carcinoma in situ * Patients are not considered to have a currently active malignancy if they have completed therapy and are considered by their physician to be at ≤ 30% risk for relapse * No known hypersensitivity reaction attributed to study drugs or to compounds of similar chemical or biological composition * No symptomatic peripheral neuropathy \> grade 1 * No other severe disease or comorbidity that would preclude study participation * No medically uncontrolled seizures * No active infection * No serious non-healing wound, ulcer, or bone fracture * No psychiatric illness or social situation that would preclude study compliance * No other severe, concurrent disease, infection, or co-morbidity that in the judgement of the investigator would constitute a hazard for study participation PRIOR CONCURRENT THERAPY: Biologic therapy * Recovered from prior cytokine therapy * At least 4 weeks since prior immunotherapy * No prior tyrosine kinase inhibitors or anti-vascular endothelial growth factor (VEGF) angiogenic inhibitors Chemotherapy * See Disease Characteristics * At least 4 weeks since prior chemotherapy * No prior oxaliplatin * Prior chemoembolization therapy allowed provided it did not affect areas of measurable disease Endocrine therapy * Prior and concurrent somatostatin analogs allowed for symptomatic control and/or control of hormone hypersecretion only provided treatment was initiated \> 3 months prior to study entry Radiotherapy * See Disease Characteristics * At least 4 weeks since prior radiotherapy and recovered * Prior radiotherapy must not affect areas of measurable disease * No concurrent radiotherapy to only site of measurable disease Surgery * Recovered from prior surgery * Prior cryotherapy allowed provided it did not affect areas of measurable disease * At least 28 days since prior major surgical procedure or open biopsy * At least 7 days since minor surgical procedure, fine-needle aspirations, or core biopsy * No prior organ allograft * No concurrent major surgery Other * At least 4 weeks since prior participation in an experimental drug study * No other concurrent investigational agents * No other concurrent anticancer therapy * No halogenated antiviral agents * Concurrent antiplatelet agents allowed